Overview of the management of differentiated thyroid cancer

被引：41

作者：

Fernandes J.K. ^{[1
]}

Day T.A. ^{[1
]}

Richardson M.S. ^{[1
]}

Sharma A.K. ^{[1
]}

机构：

[1] The Medical Univ. of South Carolina, Charleston, SC 29425

来源：

Current Treatment Options in Oncology | 2005年 / 6卷 / 1期

关键词：

Thyroid Cancer; Thyroid Carcinoma; Papillary Thyroid Carcinoma; Thyroid Nodule; Thyroid Stimulate Hormone;

D O I：

10.1007/s11864-005-0012-3

中图分类号：

学科分类号：

摘要：

Thyroid cancer is an uncommon tumor accounting for roughly 1% of all new malignancies. Differentiated (ie, papillary or follicular) thyroid carcinoma is usually asymptomatic, and frequently appears as a solitary thyroid nodule but few show cervical lymphadenopathy or metastasis to lung, bone, or liver. Fine needle aspiration (FNA) is recommended in the initial diagnostic test. Depending on the size of the lesion and other associated risk factors, most patients are treated with total or near total thyroidectomy. Postoperative radioiodine ablation is performed when tumor has a potential for recurrence. Recurrence rates and cancer-specific mortality is decreased by suppressing thyroid stimulating hormone (TSH). Long-term surveillance and follow-up with physical examination every 3 to 6 months for 2 years and then annually if patient remains cancer free. Whole body iodine scans are done every 12 months for follow-up until one negative scan (either withdrawal of thyroid hormone or rhodium complex [rh]-TSH). Thyroglobulin measurements (with antithyroglobulin antibodies) and ultrasound neck are suggested at 6 and 12 months and then annually if disease free. Copyright © 2005 by Current Science Inc.

引用

页码：47 / 57

页数：10

共 54 条

[31]

Catz B., Petit D.W., Schwartz H., Et al., Treatment of cancer of the thyroid postoperatively with suppressive thyroid medication, radioactive iodine, and thyroidstimulating hormone, Cancer, 12, pp. 371-383, (1959)

[32]

Taylor T., Specker B., Robbins J., Et al., Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma, Ann. Intern. Med., 129, pp. 622-627, (1998)

[33]

Haugen B.R., Initial treatment of differentiated thyroid carcinoma, Rev. Endocr. Metab. Disord., 1, pp. 139-145, (2000)

[34]

Baudin E., Schlumberger M., Lumbroso J., Et al., Octreotide scintigraphy in patients with differentiated thyroid carcinoma: Contribution for patients with negative radioiodine scan, J. Clin. Endocrinol. Metab., 81, pp. 2541-2544, (1996)

[35]

Klain M., Ricard M., Leboulleux S., Et al., Radioiodine therapy for papillary and follicular thyroid carcinoma, Eur. J. Nucl. Med. Mol. Imaging, 29, SUPPL. 2, pp. 479-485, (2002)

[36]

Goldman J.M., Line B.F., Aamodt R.L., Robbins J., Influence of triiodothyronine withdrawal time on 131I uptake post-thyroidectomy for thyroid cancer, J. Clin. Endocrinol. Metab., 50, pp. 734-739, (1980)

[37]

Cooper D.S., Specker B., Ho M., Et al., Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry, Thyroid, 8, pp. 737-744, (1998)

[38]

Pujol P., Daures J.P., Nsakala N., Et al., Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer, J. Clin. Endocrinol. Metab., 81, pp. 4318-4323, (1996)

[39]

Stall G.M., Harris S., Sokoll L.J., Dawson-Hughes B., Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine, Ann. Intern. Med., 113, pp. 265-269, (1990)

[40]

Biondi B., Palmieri E.A., Fazio S., Et al., Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients, J. Clin. Endocrinol. Metab., 85, pp. 4701-4705, (2000)

← 1 2 3 4 5 6 →